Abbott Laboratories is named one of the 12 Most Profitable Dividend Stocks to Buy in 2026. Evercore ISI maintains an Outperform rating on Abbott (ABT) despite trimming price target to $138 from $144. Recent stumbles led to a quarterly miss, with nutrition and diagnostics segments underperforming, leading to a 7% stock drop.

The nutrition unit at Abbott has faced challenges, with pediatric business hit by increased competition and higher manufacturing costs. Rising production costs forced the company to raise prices, impacting demand. All four business segments fell short of expectations, with nutrition sales down 8.9% and diagnostics revenue declining 2.5%.

Abbott Laboratories, a global healthcare company, saw a decline in sales in its nutrition and diagnostics segments. Despite potential as an investment, certain AI stocks may offer greater upside with less risk. For more insights on undervalued AI stocks and market trends, check out the latest report.

Read more at Yahoo Finance: Evercore ISI Says Abbott’s (ABT) Core Growth Drivers Are Still Intact